RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California. Show more

Location: 2570 West El Camino Real, Mountain View, CA, 94040, United States | Website: https://renovorx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

40.78M

52 Wk Range

$0.75 - $1.69

Previous Close

$1.12

Open

$1.14

Volume

259,429

Day Range

$1.10 - $1.25

Enterprise Value

26.48M

Cash

14.58M

Avg Qtr Burn

-2.576M

Insider Ownership

4.42%

Institutional Own.

28.51%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date